Circulating Tumor DNA Combining with Imaging Analysis for Lesion Detection of Langerhans Cell Histiocytosis in Children
2024

Using Blood Tests to Detect Langerhans Cell Histiocytosis in Children

Sample size: 119 publication 10 minutes Evidence: moderate

Author Information

Author(s): Liu Siying, Zhu Yongbing, Chen Yu, Wang Yaqin, Zhang Dedong, Zhang Jiasi, Wang Yao, Zhang Ai, Hu Qun, Liu Aiguo, Massimino Maura, Lewandowska Anna

Primary Institution: Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Hypothesis

The study examines the significance of circulating tumor DNA (ctDNA) and imaging in monitoring Langerhans cell histiocytosis (LCH) in children.

Conclusion

The findings suggest that combining ctDNA analysis with imaging can improve monitoring and treatment outcomes for children with LCH.

Supporting Evidence

  • Children with both ctDNA and imaging progression had a significantly shorter progression-free survival (PFS).
  • cfBRAFV600E mutations were linked to a higher proportion of children under 3 years of age.
  • Patients with cfBRAFV600E progression had a higher likelihood of disease relapse.
  • Imaging progression was associated with a shorter PFS compared to those without imaging progression.
  • cfDNA testing offers a less invasive alternative to traditional tissue biopsies.

Takeaway

Doctors can use a blood test to find cancer DNA in kids with a specific disease, which helps them see how well the treatment is working.

Methodology

The study used data visualization and survival analysis models to assess the relationship between ctDNA and imaging responses in LCH.

Potential Biases

Potential for bias due to the retrospective nature of the study and the exclusion of patients without LCH biopsy testimony.

Limitations

The study's sample size was limited, and the findings may not be generalizable due to geographical biases.

Participant Demographics

The cohort included 77 males (64.7%) and 42 females (35.3%), with a median age at diagnosis of 5 years.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI: 0.64–0.91

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/children11121449

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication